ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
selectively reducing exposure to consumer technology, diagnostics, and space-related companies. Recent trades across the firm's ETFs point to a growing conviction in gene-editing and genomics, highlighted by a sizable buildup in Beam Therapeutics ( NASDAQ:BEAM ). Across ARK Innovation ( ARKK ) and ARK Genomic Revolution ( ARKG ), ARK accumulated more than 195K shares of Beam, valued at roughly $5.4 billion, marking one of the firm's most aggressive recent allocations and reinforcing its focus on base-editing approaches aimed at correcting disease-causing mutations. Warning! GuruFocus has detected 1 Warning Sign with NVO. Is ARKK fairly valued? Test your thesis with our free DCF calculator. That same precision-medicine theme continued across several other purchases. ARK added roughly 236K shares of Intellia Therapeutics, extending buying activity from the prior week, while also increasing its stake in Pacific Biosciences of California ( NASDAQ:PACB ) by more than 423K shares to d
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial TransitionGlobeNewswire
- Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BEAM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- BEAM's page on the SEC website